Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

Inclusion Criteria: 1. Documented HIV-1 infection 2. Aged ≥18 years old 3. Female participant may be eligible to participate if she: is of non-childbearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea or \>=54 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy or, is of child-bearing potential, with a negative pregnancy test at both Screening and week 0 and agrees to use one of the protocol-defined methods of contraception to avoid pregnancy. 4. On current ART for at least 6 months prior to study entry 5. Current ART includes boosted protease inhibitors 6. No more than one HIV-1 plasma RNA \>50 copies/mL and \<200 copies/L (only one 'blip') in the past 6 months with a subsequent HIV-1 plasma RNA \<50 copies/mL 7. HIV-1 plasma RNA \<50 copies/mL at screening visit 8. No prior or current exposure to integrase strand transfer inhibitor (INSTI) 9. Have signed the informed consent form Exclusion Criteria: 1. Breastfeeding female 2. Pregnancy or positive UPT at screening 3. Calculated creatinine clearance as estimated by Cockcroft-Gault equation (CrCl) \<60 mL/min, 4. Alanine aminotransferase (ALT) \>2.5 x ULN, 5. Concomitant use of any of the following medications: (1) aluminum and magnesium-containing antacids, proton-pump inhibitors (2) anticonvulsants: carbamazepine, oxcarbamazepine, phenobarbital, phenytoin (3) antimycobacterials: rifabutin, rifampin, rifapentine (4) St. John's wort 6\. Alcohol or drug abuse that, in the opinion of the investigator, would interfere with completion of study procedures 7\. Any serious illness that, in the opinion of the investigator, would interfere with completion of study procedures